ESMO - Eur. Oncology· @myESMO · X·· 14 小时前评分70
正文 · 机器翻译
#ESMO26：在 INTerpath-001 III 期 #ClinicalTrial 中，Intismeran autogene 个体化 #mRNA-based #NeoantigenVaccine 疗法将接受辅助性 pembrolizumab 治疗的可切除 #melanoma 患者的复发风险降低了 42%
🔗 https://ow.ly/a6FC50ZZkJV
#InsightsbyESMO
582 浏览 · 9 赞 · 3 转发 · 0 回复
会议摘要
LBA1按 Presidential Symposium I 对上
INTerpath-001: Phase 3 study of the mRNA-based individualized neoantigen therapy (INT) intismeran autogene (intismeran) plus pembrolizumab (pembro) vs pembro alone for adjuvant treatment of resected stage IIB-IV melanoma (MEL)
https://esmocongress.esmo.orgINTerpath-001
https://esmocongress.esmo.org来源：ESMO - Eur. Oncology · x.com